Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic Acid in Breast Cancer with Bone Marrow Micrometastases
NCT00172068Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jan 2002
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zoledronic acid in breast cancer (2 arms), sponsored by Novartis. Primary endpoint: Reduction of detected tumor cells in bone marrow at 12 months. Started Jan 2002; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00172068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00172068.